Empower Pharmacy is a medication supplier, so reviewing its NAD+ offering requires different questions from reviewing an online clinic. The prescriber decides whether treatment is appropriate; the dispensing facility prepares and supplies the prescribed product. A pharmacy catalog by itself does not include a complete consultation or ongoing care program.
We reviewed Empower’s aqueous NAD+ listing, its quality information, and a historical FDA inspection document on September 19, 2026. We have not audited the facility or tested a current vial. This review explains what those sources establish, what they do not, and what a patient should ask the prescriber and pharmacy to clarify together.
Identify the exact preparation and dispensing facility. Read current quality claims alongside the dated inspection record, without treating either as a test result for your prescription.
What the aqueous NAD+ listing actually covers
The official product page lists aqueous NAD+ in more than one vial size and concentration. Aqueous identifies a liquid formulation. That matters when comparing it with a lyophilized, or dried, product that has different preparation requirements; matching ingredient names do not make the handling instructions interchangeable.
Ask the dispensing pharmacist to identify the preparation on your own prescription and explain the label. We do not turn the catalog’s concentration choices into suggested doses. The label and dosing-questions guide helps distinguish total quantity, concentration, and the separate directions your clinician must provide.
A pharmacy name does not identify the whole care service
Empower’s site describes 503A pharmacy and 503B outsourcing operations, and its product page displays availability labels for both. Those designations are not FDA approval of the NAD+ medicine. Ask which legal facility and supply pathway applies to the product your clinician proposes rather than assuming one description covers every order.
A telehealth platform using a pharmacy still has its own consultation, billing, and follow-up responsibilities. Ask who is charging you, who dispenses the prescription, and who handles each kind of concern. Our Olympia Pharmacy review discusses the same distinction for another supplier without claiming the two companies provide identical formulations or services.
Pricing needs a prescription-specific quote
The reviewed NAD+ catalog did not establish a universal consumer monthly price or a bundled medical visit. A quote from a clinic may include consultation and support, while a pharmacy charge may cover a different set of components. Do not import a price from another platform and label it Empower’s nationwide retail price.
Ask for medication, supplies, shipping, and clinical fees separately where applicable. If a prescriber changes the quantity or formulation, request an updated total before fulfillment. The cost guide is designed for exactly this problem: comparing the same service period and actual purchase rather than treating every NAD+ price as an equivalent unit.
A historical FDA observation relevant to NAD+
FDA’s December 1, 2023 Form 483 for Empower’s Houston facility recorded inspection observations, including use of non-pharmaceutical-grade components and a listed lyophilized NAD+ injectable lot. The document concerns that inspection and identified products; it is not a laboratory finding about a current aqueous vial offered to you.
As FDA explains, a Form 483 records observations and is not a final agency determination of compliance. We have not independently established the current resolution of each observation. Ask the pharmacy about corrective actions and current controls relevant to the preparation you would receive.
Put the quality claims beside product-specific records
Empower’s quality page describes its quality systems and testing processes. Those statements are useful topics for a conversation, but this review has not inspected the underlying records or verified a released batch. A general description cannot establish the result for a particular patient’s order.
Ask whether available documentation identifies the facility, ingredient sourcing, preparation, relevant lot, and tests performed. Also confirm how the pharmacy handles a quality complaint or a shipment concern. The pharmacy-verification checklist gives you a practical sequence without asking you to substitute a marketing badge for evidence.
Keep handling advice tied to the dispensed product
When a refill changes concentration, container, or formulation, have the pharmacist reconcile the new label with the prescriber’s directions. Do not reuse instructions remembered from a different vial or an online discussion. The same broad ingredient name can conceal details that matter for storage, equipment, and preparation.
Get the beyond-use date, shipping requirements, and contact information in writing. Ask what to do if a parcel is delayed or if the label is hard to read. For older readers or caregivers, a clear explanation using the actual supplied equipment is more useful than a generic injection video detached from the prescription.
Where Empower belongs in your research
Read this as a supplier review alongside the review of the clinic or platform arranging treatment. The CoreAge Rx review, our featured commercial comparison, also advises readers to obtain the actual dispensing pharmacy’s identity; this review does not establish that CoreAge uses Empower.
Compare Olympia for another pharmacy model and the FDA-approval explainer for regulatory context. Even complete supplier information cannot establish that NAD+ is appropriate for your symptoms. That decision still needs a licensed clinician and a plan to assess whether treatment should continue.
Follow the source
References & further reading
- Empower Pharmacy — aqueous NAD+ catalog
Pharmacy formulation listing, checked September 19, 2026. Not a bundled consumer telehealth plan or FDA product approval.
- Empower Pharmacy — quality systems
Company statements about its facilities and processes; this site has not audited or independently verified a current lot.
- Empower Pharmacy — patient and provider FAQs
General ordering and fulfillment information. Actual product, shipping, and billing details require confirmation.
- FDA — Empower Houston Form 483, December 1, 2023
Historical inspection observations, including a lyophilized NAD+ lot. Not a final agency determination or a finding about a current aqueous vial.
- FDA — what a Form 483 means
Explains the scope of inspection observations and how they differ from a final compliance determination.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- NABP — boards of pharmacy
Find the pharmacy regulator for your state.